Valeant ($VRX) may have terminated its relationship with controversial specialty pharmacy Philidor, but the move is going to cost it, with its dermatology and neurology businesses set to suffer. And concern is mounting among debt investors that the disruption to Valeant's cash flow could raise the risk of the company violating lender limits on its debt burden--a prospect that has some of them heading for the door, Bloomberg reports. More

The Basics of Biotech 101, 201 & 301 - Price: $299

This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. Download now.